Research
Intellectual Property
Optimum holds patents for several of the technologies developed at and by Optimum.
Publications
Following is a list of some of Optimum's publications, presentations, and abstracts.
Publications:
1.Jang, S. H., Wientjes, M.G., Lu, D., and Au, J.L. Drug delivery and transport to solid
tumors. Pharmaceutical Res., 20 (9):1337-50, 2003.
2.Lu, Ze, Yeh, T.K., Tsai, M., Au, J.L.-S., and Wientjes, M.G. Paclitaxel-loaded gelatin
nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res., 10:7677-84, 2004.
3.Yeh, T.K., Lu, Z., Au, J.L.-S. and Wientjes, M.G. Formulating paclitaxel in nanoparticles
alters its disposition. Pharmaceutical Res., 22: 867-874, 2005.
4.Lu, Z., Wientjes, T.S. and Au, J.L.-S. Nontoxic suramin treatments enhance docetaxel
activity in chemotherapy-pretreated non-small cell lung xenograft tumors. Pharmaceutical
Res., 22: 1069-1078, 2005.
5.Xin, Y., Lyness, G., Chen, D., Song, S., Wientjes, M.G., and Au, J.L. Low dose suramin as
a chemosensitizer of bladder cancer to mmc. J. Urol., 174:322-7, 2005.
6.Wang, J., Lu, Z., and Au, J.L.-S. Protection against chemotherapy-induced alopecia.
Pharmaceutical Res., 23 (11): 2505-2514, 2006.
7.Tsai, M., Lu, Z., Wang, J., Yeh, T.-K., Wientjes, M.G., and Au, J.L.-S. Effects of carrier on
disposition and antitumor activity of intraperitoneal paclitaxel. Pharmaceutical Res., 24 (9):
1691-1701, 2007.
8.Lu, D., Wientjes, M.G., Lu, Z., and Au, J.L-S. Tumor Priming Enhances Delivery and
Efficacy of Nanomedicines, J. Pharmacol. Exp. Ther., 322(1):80-8, 2007.
9.Lu, Z., Tsai, M., Lu, D., Wang, J., Wientjes, M.G., and Au, J.L.-S. Tumor penetrating
microparticles for intraperitoneal therapy of ovarian cancer. J. Pharmacol. Exp. Ther.,
327(3):673-682, 2008.
10.Lu Z, Au J, Chen L, Wang J, Fox L, Skell J, Wang R, McKay D, and Bonate PL.
Intracellular Pharmacokinetics of Tasidotin (ILX651) and Its Metabolites in A549 Cells.
(submitted to Drug Metabolism and Disposition)
Presentations:
1.Max Tsai, Ze Lu, Jie Wang, Teng-Kuang Yeh, M. Guillaume Wientjes, Jessie L.-S Au.
Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel. 34th
annual meeting and exposition of the controlled release society. July 2007.
Abstracts (most recent first):
1.Jing Li, Tong Shen, Jie Wang, Jessie L-S Au, M. Guillaume Wientjes. Nontoxic doses of
suramin enhances chemotherapy in pancreatic xenograft tumors. Proceedings of the AACR,
Vol. 49, abstract #4777, 2008.
2.Ze Lu, Max Tsai, Dan Lu, Jie Wang, M. Guillaume Wientjes, and Jessie L-S Au. Tumor
priming microparticles for intraperitoneal therapy of ovarian cancer. The AAPS Journal, Vol.
9, No. S2., abstract T3304, 2007.
3.M. Guillaume Wientjes, Leijun Hu, Xiao Hu, Yan Xin, Jing Li, Danny Chen, Liang Zhao, Jie
Wang, and Jessie L.-S. Au Physiologically based pharmacokinetics of suramin, a
chemosensitizer and prototype large negatively charged molecule. The AAPS Journal, Vol.
9, No. S2, abstract w4443, 2007.
4.Jie Wang, Ling Chen, Ze Lu, Bruce J. Dolnick, Ree Dolnick, M Guillaume Wientjes, and
Jessie L-S Au. Nanoparticulate formulation of rTS mimetic OHL improves drug stability and
anticancer efficacy. The AAPS Journal, Vol. 9, No. S2, abstract T3269, 2007.
5.Jie Wang, Yan Xin, Ling Chen, Dan Lu, M Guillaume Wientjes, Bruce J. Dolnick, Ree
Dolnick, and Jessie L-S Au. Improving the stability and efficacy of rTS mimetic OHL.
Proceedings of the AACR, Vol. 48, abstract #3909, 2007.
6.Jie Wang, Ze Lu, M. Guillaume Wientjes, and Jessie L.-S. Au. Pharmacodynamic
endpoints of chemotherapy-induced alopecia. The AAPS Journal, Vol. 8, No.S2,
abstract#T2027, 2006.
7.Ze Lu, Max Tsai, Audrie L-L. Wientjes, Andrea Miller, Jie Wang, Greg Lyness, and Jessie
L.-S. Au. Tumor priming microparticles for intraperitoneal therapy of pancreatic cancer.
Proceedings of the AACR, Vol. 47, abstract #3074, 2006.
8.Leijun Hu, Liang Zhao, Danny Chen, Xiao Hu, Jie Wang, Jessie L-S. Au, M. Guillaume
Wientjes. Physiology based pharmacokinetic study on suramin. Proceedings of the AACR,
Vol. 46, abstract #3991, 2005.
9.Danny Chen, SaeHeum Song, M. Guillaume Wientjes, TengKuang Yeh, Liang Zhao, Jie
Wang (Presenter), Migue Villalona-Calero, Greg Otterson, Rhonda Jenson, Anthony J.
Murgo, Jessie L-S Au. Low dose suramin as a chemosensitizer in patients:
pharmacokinetics, identification and validation of a dosing nomogram. Proceedings of the
AACR, Vol. 46, abstract #3990, 2005.
10.Xiao Shelley Hu, Danny Chen, SaeHeum Song, Leijun Hu, Jie Wang, Jessie L.-S. Au, and
Guillaume M. Wientjes. Interspecies scaling and physiologic based pharmacokinetic
modeling of low dose suramin as chemosensitizer. Proceedings of the AACR, Vol. 44,
abstract #825, 2003.
Intellectual Property
Optimum holds patents for several of the technologies developed at and by Optimum.
Publications
Following is a list of some of Optimum's publications, presentations, and abstracts.
Publications:
1.Jang, S. H., Wientjes, M.G., Lu, D., and Au, J.L. Drug delivery and transport to solid
tumors. Pharmaceutical Res., 20 (9):1337-50, 2003.
2.Lu, Ze, Yeh, T.K., Tsai, M., Au, J.L.-S., and Wientjes, M.G. Paclitaxel-loaded gelatin
nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res., 10:7677-84, 2004.
3.Yeh, T.K., Lu, Z., Au, J.L.-S. and Wientjes, M.G. Formulating paclitaxel in nanoparticles
alters its disposition. Pharmaceutical Res., 22: 867-874, 2005.
4.Lu, Z., Wientjes, T.S. and Au, J.L.-S. Nontoxic suramin treatments enhance docetaxel
activity in chemotherapy-pretreated non-small cell lung xenograft tumors. Pharmaceutical
Res., 22: 1069-1078, 2005.
5.Xin, Y., Lyness, G., Chen, D., Song, S., Wientjes, M.G., and Au, J.L. Low dose suramin as
a chemosensitizer of bladder cancer to mmc. J. Urol., 174:322-7, 2005.
6.Wang, J., Lu, Z., and Au, J.L.-S. Protection against chemotherapy-induced alopecia.
Pharmaceutical Res., 23 (11): 2505-2514, 2006.
7.Tsai, M., Lu, Z., Wang, J., Yeh, T.-K., Wientjes, M.G., and Au, J.L.-S. Effects of carrier on
disposition and antitumor activity of intraperitoneal paclitaxel. Pharmaceutical Res., 24 (9):
1691-1701, 2007.
8.Lu, D., Wientjes, M.G., Lu, Z., and Au, J.L-S. Tumor Priming Enhances Delivery and
Efficacy of Nanomedicines, J. Pharmacol. Exp. Ther., 322(1):80-8, 2007.
9.Lu, Z., Tsai, M., Lu, D., Wang, J., Wientjes, M.G., and Au, J.L.-S. Tumor penetrating
microparticles for intraperitoneal therapy of ovarian cancer. J. Pharmacol. Exp. Ther.,
327(3):673-682, 2008.
10.Lu Z, Au J, Chen L, Wang J, Fox L, Skell J, Wang R, McKay D, and Bonate PL.
Intracellular Pharmacokinetics of Tasidotin (ILX651) and Its Metabolites in A549 Cells.
(submitted to Drug Metabolism and Disposition)
Presentations:
1.Max Tsai, Ze Lu, Jie Wang, Teng-Kuang Yeh, M. Guillaume Wientjes, Jessie L.-S Au.
Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel. 34th
annual meeting and exposition of the controlled release society. July 2007.
Abstracts (most recent first):
1.Jing Li, Tong Shen, Jie Wang, Jessie L-S Au, M. Guillaume Wientjes. Nontoxic doses of
suramin enhances chemotherapy in pancreatic xenograft tumors. Proceedings of the AACR,
Vol. 49, abstract #4777, 2008.
2.Ze Lu, Max Tsai, Dan Lu, Jie Wang, M. Guillaume Wientjes, and Jessie L-S Au. Tumor
priming microparticles for intraperitoneal therapy of ovarian cancer. The AAPS Journal, Vol.
9, No. S2., abstract T3304, 2007.
3.M. Guillaume Wientjes, Leijun Hu, Xiao Hu, Yan Xin, Jing Li, Danny Chen, Liang Zhao, Jie
Wang, and Jessie L.-S. Au Physiologically based pharmacokinetics of suramin, a
chemosensitizer and prototype large negatively charged molecule. The AAPS Journal, Vol.
9, No. S2, abstract w4443, 2007.
4.Jie Wang, Ling Chen, Ze Lu, Bruce J. Dolnick, Ree Dolnick, M Guillaume Wientjes, and
Jessie L-S Au. Nanoparticulate formulation of rTS mimetic OHL improves drug stability and
anticancer efficacy. The AAPS Journal, Vol. 9, No. S2, abstract T3269, 2007.
5.Jie Wang, Yan Xin, Ling Chen, Dan Lu, M Guillaume Wientjes, Bruce J. Dolnick, Ree
Dolnick, and Jessie L-S Au. Improving the stability and efficacy of rTS mimetic OHL.
Proceedings of the AACR, Vol. 48, abstract #3909, 2007.
6.Jie Wang, Ze Lu, M. Guillaume Wientjes, and Jessie L.-S. Au. Pharmacodynamic
endpoints of chemotherapy-induced alopecia. The AAPS Journal, Vol. 8, No.S2,
abstract#T2027, 2006.
7.Ze Lu, Max Tsai, Audrie L-L. Wientjes, Andrea Miller, Jie Wang, Greg Lyness, and Jessie
L.-S. Au. Tumor priming microparticles for intraperitoneal therapy of pancreatic cancer.
Proceedings of the AACR, Vol. 47, abstract #3074, 2006.
8.Leijun Hu, Liang Zhao, Danny Chen, Xiao Hu, Jie Wang, Jessie L-S. Au, M. Guillaume
Wientjes. Physiology based pharmacokinetic study on suramin. Proceedings of the AACR,
Vol. 46, abstract #3991, 2005.
9.Danny Chen, SaeHeum Song, M. Guillaume Wientjes, TengKuang Yeh, Liang Zhao, Jie
Wang (Presenter), Migue Villalona-Calero, Greg Otterson, Rhonda Jenson, Anthony J.
Murgo, Jessie L-S Au. Low dose suramin as a chemosensitizer in patients:
pharmacokinetics, identification and validation of a dosing nomogram. Proceedings of the
AACR, Vol. 46, abstract #3990, 2005.
10.Xiao Shelley Hu, Danny Chen, SaeHeum Song, Leijun Hu, Jie Wang, Jessie L.-S. Au, and
Guillaume M. Wientjes. Interspecies scaling and physiologic based pharmacokinetic
modeling of low dose suramin as chemosensitizer. Proceedings of the AACR, Vol. 44,
abstract #825, 2003.
 |
 |
 |
 |
 |
 |
| Optimum Therapeutics, LLC |
